Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Silexion Therapeutics (SLXN)
NASDAQ:SLXN
SLXN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.65 - $122.01
Previous CloseN/A
Volume52.80K
Average Volume (3M)1.56M
Market Cap
$2.65M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta<0.01
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-19.70
Shares Outstanding3,995,130
10 Day Avg. Volume2,967,948
30 Day Avg. Volume1,555,333
Standard Deviation0.29
R-Squared0.23
Alpha-0.37
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$9.00Price Target Upside556.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Silexion Therapeutics News
---
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentSilexion has successfully developed a formulation that allows them to directly inject siRNA therapy into pancreatic tumors using a small needle via endoscopic ultrasound, potentially generating greater efficacy.
Market OpportunityPositive pre-clinical results of systemic administration of SIL-204 in pancreatic cancer models could allow Silexion to target both metastatic pancreatic cancer and locally advanced pancreatic cancer, materially increasing the market opportunity.
Partnership And TechnologySilexion announced they have been partnered with Evonik, a leading German specialty chemicals company to develop SIL-204.
Bears Say
Financial PositionSilexion ended the period with $2.0M in cash and equivalents, and additional capital will likely be required by year-end for conducting manufacturing work and the next clinical studies.
---
Ownership Overview
―
Insiders
0.33% Mutual Funds
― Other Institutional Investors
99.67% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
SLXN FAQ
What was Silexion Therapeutics’s price range in the past 12 months?
Silexion Therapeutics lowest stock price was $0.65 and its highest was $122.01 in the past 12 months.
What is Silexion Therapeutics’s market cap?
Silexion Therapeutics’s market cap is $2.65M.
When is Silexion Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Silexion Therapeutics’s earnings last quarter?
Currently, no data Available
Is Silexion Therapeutics overvalued?
According to Wall Street analysts Silexion Therapeutics’s price is currently Undervalued.
Does Silexion Therapeutics pay dividends?
Silexion Therapeutics does not currently pay dividends.
What is Silexion Therapeutics’s EPS estimate?
Silexion Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Silexion Therapeutics have?
Silexion Therapeutics has 3,995,130 shares outstanding.
What happened to Silexion Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Silexion Therapeutics?
Currently, no hedge funds are holding shares in SLXN
---
Company Description
Silexion Therapeutics
Moringa Acquisition Corp is a blank check company.
---
SLXN Stock 12 Month Forecast
Average Price Target
$9.00
▲(556.93% Upside)
Technical Analysis
Best Analysts Covering SLXN
1 Year
1 Year Success Rate
0/3 ratings generated profit
1 Year Average Return
-48.67%
reiterated a buy rating 10 days ago
Copying Naz Rahman's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -48.67% per trade.
---